From Nasdaq:

Investors are optimistic about growth stocks due to expected interest rate cuts from the Federal Reserve. Analysts are excited about Ginkgo Bioworks and Intellia Therapeutics, with consensus price targets suggesting potential 140% and 202% returns, respectively, over the next 12 months. Ginkgo Bioworks, a synthetic biology company, lost $686 million in 2023 and struggles with profitability. Intellia Therapeutics, specializing in CRISPR-based gene therapies, shows promise with an experimental treatment for transthyretin amyloidosis. Despite potential, both stocks carry significant risk and may not be suitable for most growth-focused investors.



Read more: 2 Growth Stocks That Could Rocket 144% and 202% Higher This Year, According to Wall Street